Alle News

Researchers at Helmholtz Munich have found that the body begins signaling the risk of type 2 diabetes many years before the disease is diagnosed. In a long-term study, the team examined hundreds of blood metabolites – small molecules that reflect…

Helmholtz Munich is part of the EU research initiative PROBE, which aims to fundamentally transform the way osteoarthritis is diagnosed and treated. The project is funded through HORIZON EUROPE by the Innovative Health Initiative and has a total…

A recent study led by Prof. Eleftheria Zeggini, Director of the Institute of Translational Genomics at Helmholtz Munich, provides new insights into how genetic risk for type 2 diabetes (T2D) can influence a wide range of health conditions beyond…

A new study, led by Prof. Eleftheria Zeggini, Director of the Institute of Translational Genomics at Helmholtz Munich, and Prof. Anette-Gabriele Ziegler, Director of the Institute of Diabetes Research at Helmholtz Munich, has revealed a significant…

Osteoarthritis is the leading cause of disability and chronic pain worldwide, affecting an estimated 595 million people globally. Projections suggest that this number will rise to 1 billion by 2050. Despite its profound impact on individuals and…

Digital DNA Strand Map Displaying Real time Genetic Data Retrieval and Storage Concept

Helmholtz Munich launches the Helmholtz Munich Imputation Server, providing an imputation service for researchers based in the European Union (EU) and beyond. Imputation is the statistical inference of unobserved genotypes and plays a pivotal role in…

Tracking Metabolic Clues Years Before Type 2 Diabetes Develops

Helmholtz Munich Launches Pioneering Osteoarthritis Research Project With EU Partners

Genetic Links Between Type 2 Diabetes and Multiple Health Conditions

Genetic Connection Between Newborn Blood Proteins and Type 1 Diabetes

Osteoarthritis: Largest Genome-Wide Association Study Uncovers Drug Targets and Therapy Opportunities

Helmholtz Munich Launches Imputation Server